echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Nature Medicine of East China Normal University reports the world's first clinical results of CRISPR gene editing in children with β0/β0 severe thalassaemia

    Nature Medicine of East China Normal University reports the world's first clinical results of CRISPR gene editing in children with β0/β0 severe thalassaemia

    • Last Update: 2022-09-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Beta-thalassemia is an inherited hemolytic disease that is prevalent worldwide and is one of the most common monogenic diseases 1


    Recently, the team of Wu Yuxuan, Liu Mingyao, and Li Dali from the School of Life Sciences of East China Normal University, Fu Bin's team from Xiangya Hospital of Central South University, and Bangyao Biology jointly published a paper entitled CRISPR–Cas9-mediated gene editing of the BCL11A enhancer in the journal Nature Medicine.


    Disruption of the GATA1 binding site of the +58 BCL11A erythroid enhancer by gene editing induces γ-globin expression, a promising therapeutic strategy for alleviating β-hemoglobinopathies caused by mutations in the HBB gene 5-7


    The trial transplanted gene-edited autologous hematopoietic stem progenitor cells (HSPCs) into two pediatric patients, one with the β0/β0 genotype classified as the most severe type of TDT; the other treated with Also belongs to TDT


    Changes of red blood cells and hemoglobin after transplantation, the proportion of F cells and iron metabolism data

    Exploratory analysis of the indel patterns in the edited PBMCs revealed that no abnormal clonal expansion was observed during the nearly two-year follow-up period


    Expression of B-cell proliferation-related genes in B-cell clusters from healthy donors and gene-edited patients

    In conclusion, this study provides proof-of-principle that engraftment and long-term engraftment of CRISPR/Cas9-edited autologous HSPCs can be achieved, and confirms that sustained elevation of fetal hemoglobin levels is sufficient to ameliorate transfusion-dependent β-thalassemia, even for β-beads.


    Professor Wu Yuxuan, Professor Liu Mingyao and Professor Li Dali are the co-corresponding authors of the paper



    references

    1 Piel, FB The present and future global burden of the inherited disorders of hemoglobin.


    2 Yin, XL et al.


    3 Modell, B.


    4 Li, C.


    5 Wu, Y.


    6 Wang, L.


    7 Demirci, S.



    Full text link:

    https://doi.
    org/10.
    1038/s41591-022-01906-z

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.